Literature DB >> 28616405

Endoscopic treatment for distal malignant biliary obstruction.

Kazuya Matsumoto1, Yohei Takeda1, Takumi Onoyama1, Soichiro Kawata1, Hiroki Kurumi1, Hiroki Koda1, Taro Yamashita1, Hajime Isomoto1.   

Abstract

Distal malignant biliary obstruction (MBO) leads to obstructive jaundice as a result of when the bile excretion from the liver is disturbed and induces hepatic failure and sepsis, which when complicated with cholangitis, it becomes necessary to perform drainage for the MBO. For biliary drainage, we can perform a surgical bypass operation, percutaneous transhepatic biliary drainage (PTBD), endoscopic biliary drainage (EBD) via duodenal papilla, or endoscopic ultrasound (EUS)-guided biliary drainage (EUS-BD), which is a transgastrointestinal biliary drainage. Although currently we usually perform EBD for distal MBO to begin with, the choice is different for biliary drainage in patients in whom EBD has failed in a preoperative case or an unresectable case. In other words, we choose PTBD for preoperative cases, and PTBD or EUS-BD according to the ability of the institution for their procedures when EBD has failed. It is desirable not to choose a plastic stent (PS) but a self-expandable metallic stent (SEMS), in particular for the unresectable cases of pancreatic cancer it is desirable not to choose an uncovered SEMS but a covered SEMS in EBD. Nevertheless, further examinations are expected to decide which, a covered or uncovered SEMS, we should choose in unresectable biliary tract cancer (BTC) and whether we should select PS, SEMS or ENBD in preoperative cases.

Entities:  

Keywords:  EUS-guided biliary drainage (EUS-BD), plastic stent (PS); Malignant biliary obstruction (MBO); endoscopic biliary drainage (EBD); self-expandable metallic stent (SEMS)

Year:  2017        PMID: 28616405      PMCID: PMC5464936          DOI: 10.21037/atm.2017.02.22

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  49 in total

1.  Drainage of gallbladder fossa fluid collections with endoprosthesis placement under endoscopic ultrasound guidance: a preliminary report of two cases.

Authors:  M Kahaleh; P Wang; V M Shami; J Tokar; P Yeaton
Journal:  Endoscopy       Date:  2005-04       Impact factor: 10.093

Review 2.  Management of acute cholangitis as a result of occlusion from a self-expandable metallic stent in patients with malignant distal and hilar biliary obstructions.

Authors:  Hideyuki Shiomi; Kazuya Matsumoto; Hiroyuki Isayama
Journal:  Dig Endosc       Date:  2017-04       Impact factor: 7.559

3.  Endoscopic cannulation of the ampulla of vater: a preliminary report.

Authors:  W S McCune; P E Shorb; H Moscovitz
Journal:  Ann Surg       Date:  1968-05       Impact factor: 12.969

4.  Initial experience with EUS-guided cholangiopancreatography for biliary and pancreatic duct drainage: a Spanish national survey.

Authors:  Juan J Vila; Manuel Pérez-Miranda; Enrique Vazquez-Sequeiros; Monder Abu-Suboh Abadia; Antonio Pérez-Millán; Ferrán González-Huix; Joan Gornals; Julio Iglesias-Garcia; Carlos De la Serna; José R Aparicio; José C Subtil; Alberto Alvarez; Felipe de la Morena; Jesús García-Cano; María A Casi; Angel Lancho; Angel Barturen; Santiago J Rodríguez-Gómez; Alejandro Repiso; Diego Juzgado; Francisco Igea; Ignacio Fernandez-Urien; Juan A González-Martin; José R Armengol-Miró
Journal:  Gastrointest Endosc       Date:  2012-09-26       Impact factor: 9.427

5.  Fully covered self-expandable metal stents are effective and safe to treat distal malignant biliary strictures, irrespective of surgical resectability status.

Authors:  Ali A Siddiqui; Vaibhav Mehendiratta; David Loren; Shih-Kuang Hong; Thomas Kowalski
Journal:  J Clin Gastroenterol       Date:  2011-10       Impact factor: 3.062

6.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.

Authors:  J R Andersen; S M Sørensen; A Kruse; M Rokkjaer; P Matzen
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

7.  Use of expandable metallic biliary stents in resectable pancreatic cancer.

Authors:  Sanjeev M Wasan; William A Ross; Gregg A Staerkel; Jeffrey H Lee
Journal:  Am J Gastroenterol       Date:  2005-09       Impact factor: 10.864

8.  Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study.

Authors:  A Aziz Aadam; Douglas B Evans; Abdul Khan; Young Oh; Kulwinder Dua
Journal:  Gastrointest Endosc       Date:  2012-04-05       Impact factor: 9.427

9.  A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct.

Authors:  K Knyrim; H J Wagner; J Pausch; N Vakil
Journal:  Endoscopy       Date:  1993-03       Impact factor: 10.093

10.  Antireflux Metal Stent as a First-Line Metal Stent for Distal Malignant Biliary Obstruction: A Pilot Study.

Authors:  Tsuyoshi Hamada; Hiroyuki Isayama; Yousuke Nakai; Osamu Togawa; Naminatsu Takahara; Rie Uchino; Suguru Mizuno; Dai Mohri; Hiroshi Yagioka; Hirofumi Kogure; Saburo Matsubara; Natsuyo Yamamoto; Yukiko Ito; Minoru Tada; Kazuhiko Koike
Journal:  Gut Liver       Date:  2017-01-15       Impact factor: 4.519

View more
  3 in total

1.  Stenting with high-intensity focused ultrasound ablation for distal biliary obstruction caused by pancreatic carcinoma: a meta-analysis.

Authors:  Xin-Qiang Liu; Sha-Sha Cui; Yu-Ling Kan; Jia-Fen Wang; Yuan-Shun Xu; Feng-Qin Zhang; Pan-Hao Rong
Journal:  Prz Gastroenterol       Date:  2021-07-14

Review 2.  TXNIP: A Double-Edged Sword in Disease and Therapeutic Outlook.

Authors:  Min Pan; Fengping Zhang; Kai Qu; Chang Liu; Jingyao Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-04-11       Impact factor: 7.310

Review 3.  Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers.

Authors:  Yiting Chen; Jieling Ning; Wenjie Cao; Shuanglian Wang; Tao Du; Jiahui Jiang; Xueping Feng; Bin Zhang
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.